erlotinib (Tarceva)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Tarceva

Indications

Contraindications

Dosage

100-150 mg PO QD

Tabs: 25 mg, 100 mg, 150 mg

Pharmacokinetics

Adverse effects

Drug interactions

Laboratory

Mechanism of action

Notes

Cost = $2000/month

More general terms

References

  1. Jump up to: 1.0 1.1 Prescriber's Letter 12(1):5 2005 FDA Approves New Drug for the Most Common Type of Lung Cancer Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210104&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Jump up to: 2.0 2.1 Journal Watch 25(17):136, 2005 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16014882
    Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005 Jul 14;353(2):133-44. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16014883
    Doroshow JH. Targeting EGFR in non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):200-2. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16014890
  3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 23; [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/17452677
  4. Jump up to: 4.0 4.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tarceva
  5. Jump up to: 5.0 5.1 5.2 5.3 FDA MedWatch http://www.fda.gov/medwatch/safety/2009/safety09.htm#Tarceva
  6. Jump up to: 6.0 6.1 Lim MY Non-Small Cell Lung Cancer: 5 Management Challenges. Medscape. Nov 30, 2016 http://reference.medscape.com/features/slideshow/non-small-cell-lung-cancer
  7. Jump up to: 7.0 7.1 PubChem: 176870
  8. Jump up to: 8.0 8.1 Medscape: erlotinib (Tarceva) Antineoplastics, Tyrosine Kinase Inhibitor; Antineoplastics, EGFR Inhibitor
  9. Jump up to: 9.0 9.1 Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol. 2010 Dec;6(12):1827-32. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21142856 Free PMC Article
    Coudert B, Ciuleanu T, Park K et al SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012 Feb;23(2):388-94. Epub 2011 May 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21610154
  10. Jump up to: 10.0 10.1 Rosell R, Carcereny E, Gervais R et al Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22285168

Database